---
title: "Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product comparison"
description: "Formulary evidence on Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product comparison. Topics: Claseprubart: mechanism, route, dosing interval, and approval status; Immune globulin intravenous 10%: Gamunex-C; Immune globulin intravenous 10%: Privigen; Immune globulin intravenous 10%: Panzyga; 8 further topics. 12 evidence topics quoted from 14 sources."
canonical: "https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description/product-comparison"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product comparison

<a id="heading-2.1.2.14"></a>

## 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

### Claseprubart: mechanism, route, dosing interval, and approval status

| Attribute | Quoted text |
| --- | --- |
| Approval status | “Claseprubart is an investigational agent that is not approved as a therapy in any indication in any jurisdiction worldwide.” |
| Mechanism of action | “potent monoclonal antibody engineered to selectively target the classical pathway by inhibiting only the active form of the C1s protein” |
| Route and dosing interval | “Claseprubart is designed to enable a more convenient, subcutaneous (S.C.), self-administered injection dosed as infrequently as once every two or four weeks.” |
| Regimen in the CIDP phase 3 trial | “The Phase 3 CAPTIVATE trial of claseprubart 300mg/2mL S.C. Q2W” |

Source: [Dianthus Therapeutics (2026g)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000039/dnth-ex99_1.htm)

> “Claseprubart intravenous (IV) loading dose on Day 1.”
> “Claseprubart subcutaneous (SC) once every 2 weeks for up to 13 weeks.”

Source: [ClinicalTrials.gov NCT06858579](https://clinicaltrials.gov/study/NCT06858579)

<a id="topic-2.1.2.14-2"></a>

### Immune globulin intravenous 10%: Gamunex-C

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “GAMUNEX-C FlexBag, [immune globulin injection (human), 10%, caprylate/chromatography purified] for intravenous use.” |
| CIDP indication | “GAMUNEX-C FlexBag is indicated for the treatment of CIDP in adults to improve neuromuscular disability and impairment and for maintenance therapy to prevent relapse.” |
| Mechanism of action in CIDP | “The precise mechanism of action in CIDP has not been fully elucidated.” |
| CIDP dosing and interval | “GAMUNEX-C FlexBag may be administered as a maintenance infusion of 1 g/kg (10 mL/kg) administered over 1 day or divided into two doses of 0.5 g/kg (5 mL/kg) given on two consecutive days, every 3 weeks.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2003” |

Source: [Gamunex-C prescribing information (2026)](https://www.fda.gov/media/70738/download)

<a id="topic-2.1.2.14-3"></a>

### Immune globulin intravenous 10%: Privigen

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “PRIVIGEN, Immune Globulin Intravenous (Human), 10% Liquid” |
| CIDP indication | “Chronic inflammatory demyelinating polyneuropathy (CIDP) in adults (1.3)” |
| Limitation of use in CIDP | “PRIVIGEN maintenance therapy in CIDP has not been studied beyond 6 months.” |
| Mechanism of action | “The mechanism of action has not been fully elucidated” |
| CIDP dosing and interval | “Maintenance dose: 1 g/kg (10 mL/kg) administered in 1 to 2 infusions on consecutive days, every 3 weeks” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2007” |

Source: [Privigen prescribing information (2025)](https://www.fda.gov/media/83304/download)

<a id="topic-2.1.2.14-4"></a>

### Immune globulin intravenous 10%: Panzyga

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “PANZYGA, (immune globulin intravenous, human - ifas) 10% Liquid Preparation” |
| CIDP indication | “Chronic inflammatory demyelinating polyneuropathy (CIDP) in adults” |
| Mechanism of action in CIDP | “The mechanism of action of immunoglobulins in the treatment of CIDP in adults has not been fully elucidated.” |
| CIDP dosing and interval | “Maintenance dose: 1-2 g/kg (10-20 mL/kg) every 3 weeks divided in 2 doses given over 2 consecutive days” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2018” |

Source: [Panzyga prescribing information (2021)](https://www.fda.gov/media/115397/download)

<a id="topic-2.1.2.14-5"></a>

### Immune globulin intravenous 10%: Gammagard Liquid

| Attribute | Prescribing information |
| --- | --- |
| Product | “GAMMAGARD LIQUID is an immune globulin infusion (human)” |
| CIDP indication | “Therapy to improve neuromuscular disability and impairment in adult patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).” |
| Limitation of use in CIDP | “Safety and effectiveness of GAMMAGARD LIQUID has not been studied in immunoglobulin-naïve patients with CIDP.” |
| Route in CIDP | “CIDP: Intravenous (IV)” |
| Mechanism of action in CIDP | “The mechanism of action of immunoglobulins in the treatment of CIDP in adults has not been fully elucidated but may include immunomodulatory effects.” |
| CIDP dosing and interval | “Maintenance dose is 1 g/kg in divided doses over 1 to 4 consecutive days, every 3 weeks.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2005” |

Source: [Gammagard Liquid prescribing information (2024)](https://www.fda.gov/media/191699/download)

<a id="topic-2.1.2.14-6"></a>

### Immune globulin subcutaneous 20%: Hizentra

| Attribute | Prescribing information |
| --- | --- |
| Product and route | “HIZENTRA is an Immune Globulin Subcutaneous (Human) (IGSC), 20% Liquid” |
| CIDP indication | “HIZENTRA is indicated for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP) as maintenance therapy to prevent relapse of neuromuscular disability and impairment.” |
| Mechanism of action | “The mechanism of action has not been fully elucidated, but may include immunomodulatory effects.” |
| CIDP dosing | “Recommended subcutaneous dose is 0.2 g/kg (1 mL/kg) body weight per week.” |
| CIDP dosing interval | “CIDP: Administer weekly.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2010” |

Source: [Hizentra prescribing information (2021)](https://www.fda.gov/media/78466/download)

<a id="topic-2.1.2.14-7"></a>

### Immune globulin 10% with recombinant human hyaluronidase: HyQvia

| Attribute | Prescribing information |
| --- | --- |
| Product | “HYQVIA is an Immune Globulin Infusion (Human), 10% with a Recombinant Human Hyaluronidase (rHuPH20)” |
| CIDP indication | “Maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP)” |
| Route | “For subcutaneous use only” |
| Mechanism of action in CIDP | “The mechanism of action of immunoglobulins in the treatment of CIDP in adults has not been fully elucidated but may include immunomodulatory effects.” |
| Role of hyaluronidase | “The rHuPH20 of HYQVIA increases permeability of the subcutaneous tissue by temporarily depolymerizing hyaluronan.” |
| CIDP dosing and interval | “The starting dose and dosing frequency of HYQVIA is the same as the patient’s previous IGIV treatment. The typical dosing interval range in the clinical trial for HYQVIA was 2 to 4 weeks.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2014” |

Source: [HyQvia prescribing information (2026)](https://www.fda.gov/media/89844/download)

<a id="topic-2.1.2.14-8"></a>

### Neonatal Fc receptor blocker: Vyvgart Hytrulo

| Attribute | Prescribing information |
| --- | --- |
| Product | “VYVGART HYTRULO is a combination of efgartigimod alfa, a neonatal Fc receptor blocker, and hyaluronidase, an endoglycosidase” |
| CIDP indication | “chronic inflammatory demyelinating polyneuropathy (CIDP)” |
| Mechanism of action | “Efgartigimod alfa is a human IgG1 antibody fragment that binds to the neonatal Fc receptor (FcRn), resulting in the reduction of circulating IgG.” |
| Route | “VYVGART HYTRULO is for subcutaneous use only.” |
| Self-administration | “Prefilled syringe can be administered by patients and/or caregivers.” |
| CIDP dosing interval | “Administer as once weekly injections.” |
| CIDP dose, prefilled syringe | “Prefilled syringe: 1,000 mg efgartigimod alfa and 10,000 units hyaluronidase administered over approximately 20 to 30 seconds.” |
| Initial U.S. approval (any indication) | “Initial U.S. Approval: 2023” |

Source: [Vyvgart Hytrulo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761304s018lbl.pdf)

> “In June 2024, Vyvgart Hytrulo, marketed by argenx, was approved for the treatment of CIDP.”

Source: [Dianthus Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1690585/000169058526000006/dnth-20251231.htm)

<a id="topic-2.1.2.14-9"></a>

### Investigational C1s inhibitor riliprubart: phase 3 status

> “Sanofi today announced that the riliprubart MOBILIZE phase 3 study (clinical study identifier: NCT06290128) in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) refractory to standard-of-care treatment will be stopped.”
> “This decision follows an interim analysis by an independent data monitoring committee, which determined that the MOBILIZE study is unlikely to provide sufficient efficacy.”
> “The continuation of other ongoing studies with riliprubart, including the VITALIZE phase 3 study (clinical study identifier: NCT06290141) in IVIg-treated patients with CIDP, will be evaluated accordingly.”
> “Riliprubart (SAR445088, BIVV020) is an IgG4 humanized monoclonal antibody that selectively inhibits activated C1s in the classical complement pathway of the innate immune system.”

Source: [Sanofi (2026)](https://www.sanofi.com/en/media-room/press-releases/2026/2026-06-10-05-00-00-3309444)

<a id="topic-2.1.2.14-10"></a>

### Investigational C2 inhibitor empasiprubart: phase 3 status

> “empasiprubart is a differentiated therapeutic mAb targeting C2”
> “argenx is advancing two Phase 3 clinical trials of empasiprubart in CIDP: EMVIGORATE and EMNERGIZE.”
> “Topline results from both EMVIGORATE and EMNERGIZE are expected in the second half of 2027.”
> “In addition to an IV formulation”

Source: [argenx annual report (2026)](https://reports.argenx.com/2025/argenx-group/our-products-and-product-candidates/empasiprubart-development.html)

<a id="topic-2.1.2.14-11"></a>

### Investigational C2 inhibitor empasiprubart: placebo-controlled phase 3 trial registration (EMNERGIZE)

> “A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Empasiprubart IV in Adults With Chronic Inflammatory Demyelinating Polyneuropathy”
> “The study consists of a part A where participants will either receive empasiprubart or placebo for 24 weeks (6 months). Following part A, participants will enter part B in which all participants will receive empasiprubart for 96 weeks (24 months).”
> “Reduction of ≥1 point compared with baseline in aINCAT score at week 24”
> “Study Start (Actual) 2025-09-16”
> “Primary Completion (Estimated) 2027-10-07”
> “Enrollment (Estimated) 160”

Source: [ClinicalTrials.gov NCT07091630](https://clinicaltrials.gov/study/NCT07091630)

<a id="topic-2.1.2.14-12"></a>

### Investigational C2 inhibitor empasiprubart: head-to-head phase 3 trial registration against intravenous immunoglobulin (EMVIGORATE)

> “A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy”
> “This study consists of a Part A where participants will either receive empasiprubart and a placebo resembling IVIg, or IVIg and a placebo resembling empasiprubart for 24 weeks (6 months). Following Part A, participants will enter Part B in which all participants will receive empasiprubart for 96 weeks (24 months).”
> “Study Start (Actual) 2025-08-22”
> “Primary Completion (Estimated) 2027-09”
> “Enrollment (Estimated) 218”

Source: [ClinicalTrials.gov NCT06920004](https://clinicaltrials.gov/study/NCT06920004)

## Related pages
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Terms and abbreviations](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/terms-and-abbreviations.md)
- [Claseprubart (DNTH103): Chronic inflammatory demyelinating polyneuropathy](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/executive-summary.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Product information and disease description](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/product-information-and-disease-description.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Clinical evidence](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/clinical-evidence.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: Economic information and modeling report](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/economics.md)
- [Claseprubart (DNTH103) in Chronic inflammatory demyelinating polyneuropathy: References](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references) · [Markdown](https://www.evicenter.com/drugs/claseprubart--chronic-inflammatory-demyelinating-polyneuropathy/references.md)
